Latest & greatest articles for adverse events

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adverse events or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adverse events and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for adverse events

161. Disclosure and Discussion of Adverse Events

Disclosure and Discussion of Adverse Events Disclosure and Discussion of Adverse Events - ACOG Menu ▼ Disclosure and Discussion of Adverse Events Page Navigation ▼ Number 681, December 2016 (Replaces Committee Opinion No. 520, March 2012) (Reaffirmed 2019) Committee on Patient Safety and Quality Improvement This Committee Opinion was developed by the American College of Obstetricians and Gynecologists’ Committee on Patient Safety and Quality Improvement in collaboration with committee member (...) Edward P. Denious, MD. This document reflects emerging concepts on patient safety and is subject to change. The information should not be construed as dictating an exclusive course of treatment or procedure to be followed. Disclosure and Discussion of Adverse Events ABSTRACT: Adverse outcomes, preventable or otherwise, are a reality of medical care. Most importantly, adverse events affect patients, but they also affect health care practitioners. Disclosing information about adverse events has

2016 American College of Obstetricians and Gynecologists

162. Prospective evaluation of sedation-related adverse events in pediatric patients ventilated for acute respiratory failure

Prospective evaluation of sedation-related adverse events in pediatric patients ventilated for acute respiratory failure PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2015 PedsCCM Evidence-Based Journal Club

163. A Systematic Review of Prospective Studies Reporting Adverse Events of Commonly Used Opioids for Cancer-Related Pain: A Call for the Use of Standardized Outcome Measures (PubMed)

A Systematic Review of Prospective Studies Reporting Adverse Events of Commonly Used Opioids for Cancer-Related Pain: A Call for the Use of Standardized Outcome Measures Data on the tolerability of opioids in patients with cancer-related pain are limited. Here, we report a systematic review that includes all published prospective studies reporting adverse events (AEs) of morphine, oxycodone, fentanyl, methadone, or hydromorphone for cancer-related pain in patients naive for these opioids. We (...) influence outcome rates. Although AEs are an important issue in daily clinical practice, realistic incidence rates of AEs per type of opioid are unknown because of the immense heterogeneity among studies.Although opioid-related adverse events are an important issue when treating cancer-related pain, realistic rates of adverse events per type of opioid are unknown because of immense heterogeneity among studies and lack of systematic assessment and reporting. There is an urgent need for studies

2015 EvidenceUpdates

164. Association of Tdap Vaccination With Acute Events and Adverse Birth Outcomes Among Pregnant Women With Prior Tetanus-Containing Immunizations. (PubMed)

Association of Tdap Vaccination With Acute Events and Adverse Birth Outcomes Among Pregnant Women With Prior Tetanus-Containing Immunizations. The Advisory Committee on Immunization Practices (ACIP) recommends the tetanus, diphtheria, and acellular pertussis (Tdap) vaccine for pregnant women during each pregnancy, regardless of prior immunization status. However, safety data on repeated Tdap vaccination in pregnancy is lacking.To determine whether receipt of Tdap vaccine during pregnancy (...) administered in close intervals from prior tetanus-containing vaccinations is associated with acute adverse events in mothers and adverse birth outcomes in neonates.A retrospective cohort study in 29,155 pregnant women aged 14 through 49 years from January 1, 2007, through November 15, 2013, using data from 7 Vaccine Safety Datalink sites in California, Colorado, Minnesota, Oregon, Washington, and Wisconsin.Women who received Tdap in pregnancy following a prior tetanus-containing vaccine less than 2 years

Full Text available with Trip Pro

2015 JAMA

165. Emergency Department Visits for Adverse Events Related to Dietary Supplements. (PubMed)

Emergency Department Visits for Adverse Events Related to Dietary Supplements. Dietary supplements, such as herbal or complementary nutritional products and micronutrients (vitamins and minerals), are commonly used in the United States, yet national data on adverse effects are limited.We used nationally representative surveillance data from 63 emergency departments obtained from 2004 through 2013 to describe visits to U.S. emergency departments because of adverse events related to dietary (...) supplements.On the basis of 3667 cases, we estimated that 23,005 (95% confidence interval [CI], 18,611 to 27,398) emergency department visits per year were attributed to adverse events related to dietary supplements. These visits resulted in an estimated 2154 hospitalizations (95% CI, 1342 to 2967) annually. Such visits frequently involved young adults between the ages of 20 and 34 years (28.0% of visits; 95% CI, 25.1 to 30.8) and unsupervised children (21.2% of visits; 95% CI, 18.4 to 24.0). After

2015 NEJM

166. Adverse events associated with single dose oral analgesics for acute postoperative pain in adults - an overview of Cochrane reviews. (PubMed)

Adverse events associated with single dose oral analgesics for acute postoperative pain in adults - an overview of Cochrane reviews. This is an update of a Cochrane overview published in Issue 9, 2011; that overview considered both efficacy and adverse events. This overview considers adverse events, with efficacy dealt with in a separate overview.Thirty-nine Cochrane reviews of randomised trials have examined the adverse events associated with individual drug interventions in acute (...) postoperative pain. This overview brings together the results of those individual reviews.To provide an overview of adverse event rates associated with single-dose oral analgesics, compared with placebo, for acute postoperative pain in adults.We identified systematic reviews in The Cochrane Database of Systematic Reviews on The Cochrane Library through a simple search strategy. All reviews were overseen by a single review group. We extracted information related to participants experiencing any adverse event

Full Text available with Trip Pro

2015 Cochrane

167. The Incremental Risk of Coronary Stents on Postoperative Adverse Events: A Matched Cohort Study (PubMed)

The Incremental Risk of Coronary Stents on Postoperative Adverse Events: A Matched Cohort Study To determine the incremental risk of coronary stents on adverse events in surgical patients and whether it varies over time from stent placement.Postoperative adverse cardiac events decrease as the time from stent placement increases, but the risk attributable to the stent versus the underlying cardiac disease is uncertain, as prior studies lack a control surgical population.Data for patients (...) and nonstented populations were compared across time after stent placement.Adverse cardiac events followed surgery in 531 (5.7%) of the 9391 patients with stent and 680 (3.6%) of the 18,782 patients without stent (P < 0.001). In adjusted models, 30-day postoperative MI (odds ratio = 1.90; 95% confidence interval, 1.57-2.30) and revascularization (odds ratio = 2.03; 95% confidence interval, 1.65-2.50) but not mortality (odds ratio = 0.84; 95% confidence interval, 0.69-1.02) were higher in the stented cohort

2015 EvidenceUpdates

168. Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis. (PubMed)

Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis. To determine the risk of neuropsychiatric adverse events associated with use of varenicline compared with placebo in randomised controlled trials.Systematic review and meta-analysis comparing study effects using two summary estimates in fixed effects models, risk differences, and Peto odds ratios.Medline, Embase, PsycINFO, the Cochrane Central Register of Controlled Trials (CENTRAL (...) ), and clinicaltrials.gov.Randomised controlled trials with a placebo comparison group that reported on neuropsychiatric adverse events (depression, suicidal ideation, suicide attempt, suicide, insomnia, sleep disorders, abnormal dreams, somnolence, fatigue, anxiety) and death. Studies that did not involve human participants, did not use the maximum recommended dose of varenicline (1 mg twice daily), and were cross over trials were excluded.In the 39 randomised controlled trials (10,761 participants), there was no evidence

Full Text available with Trip Pro

2015 BMJ

169. The incremental risk of noncardiac surgery on adverse cardiac events following coronary stenting (PubMed)

The incremental risk of noncardiac surgery on adverse cardiac events following coronary stenting Recent coronary stent placement and noncardiac surgery contribute to the risk of adverse cardiac events, but the relative contributions of these two factors have not been quantified.This research was designed to determine the incremental risk of noncardiac surgery on myocardial infarction (MI) and coronary revascularization following coronary stenting.A U.S. retrospective cohort study of patients (...) it remained stable out to 24 months. Factors associated with a significant reduction in risk following surgery more than 6 months post-stent included elective inpatient procedures (ΔRD: 1.8%; p = 0.01), high-risk surgery (ΔRD: 3.7%; p = 0.01), and drug-eluting stent (DES) (ΔRD: 1.3%; p = 0.01).The incremental risk of noncardiac surgery on adverse cardiac events among post-stent patients is highest in the initial 6 months following stent implantation and stabilizes at 1.0% after 6 months. Elective, high

Full Text available with Trip Pro

2015 EvidenceUpdates

170. Global coronary flow reserve is associated with adverse cardiovascular events independently of luminal angiographic severity and modifies the effect of early revascularization (PubMed)

Global coronary flow reserve is associated with adverse cardiovascular events independently of luminal angiographic severity and modifies the effect of early revascularization Coronary flow reserve (CFR), an integrated measure of focal, diffuse, and small-vessel coronary artery disease (CAD), identifies patients at risk for cardiac death. We sought to determine the association between CFR, angiographic CAD, and cardiovascular outcomes.Consecutive patients (n=329) referred for invasive coronary (...) , global ischemia, and early revascularization, CFR and CAD prognostic index were independently associated with events (hazard ratio for unit decrease in CFR, 2.02; 95% confidence interval, 1.20-3.40; P=0.008; hazard ratio for 10-U increase in CAD prognostic index, 1.17; 95% confidence interval, 1.01-1.34; P=0.032). Subjects with low CFR experienced rates of events similar to those of subjects with high angiographic scores, and those with low CFR or high CAD prognostic index showed the highest risk

Full Text available with Trip Pro

2015 EvidenceUpdates

171. Cohort study: For patients who underwent elective non-cardiac surgery, a history of stroke is associated with an increased risk of major adverse cardiovascular events and death, particularly if time elapsed between stroke and surgery is less than 9?months

Cohort study: For patients who underwent elective non-cardiac surgery, a history of stroke is associated with an increased risk of major adverse cardiovascular events and death, particularly if time elapsed between stroke and surgery is less than 9?months For patients who underwent elective non-cardiac surgery, a history of stroke is associated with an increased risk of major adverse cardiovascular events and death, particularly if time elapsed between stroke and surgery is less than 9 months (...) accounts OR managers of institutional accounts Username * Password * your user name or password? You are here For patients who underwent elective non-cardiac surgery, a history of stroke is associated with an increased risk of major adverse cardiovascular events and death, particularly if time elapsed between stroke and surgery is less than 9 months Article Text Prognosis Cohort study For patients who underwent elective non-cardiac surgery, a history of stroke is associated with an increased risk

Full Text available with Trip Pro

2015 Evidence-Based Medicine (Requires free registration)

172. A cost-effectiveness analysis of maternal genotyping to guide treatment for postpartum pain and avert infant adverse events

A cost-effectiveness analysis of maternal genotyping to guide treatment for postpartum pain and avert infant adverse events The Hospital for Sick Children Technology Assessment at SickKids (TASK) FULL REPORT A COST-EFFECTIVENESS ANALYSIS OF MATERNAL GENOTYPING TO GUIDE TREATMENT FOR POSTPARTUM PAIN AND AVERT INFANT ADVERSE EVENTS Authors: Myla E. Moretti, PhD Research Associate, Clinical Trials Support Unit, The Hospital for Sick Children, Toronto Daniella F. Lato, BSc Research Assistant (...) for SF-36v2 (n=33) 43 Table 3.6: Summaries of the SF-6D Scores (n=33) 44 Table 3.7: Summary of State-Trait Anxiety Inventory Scores (n=33) 44 Table 3.8: Summary of Linear Regression Analysis for Differences in HRQoL, State, Trait and SF-6D Scores 45 Table 3.9: Base Case Cost Consequence Analysis for Adverse Events 45 Table 3.10 Base Case Cost Consequence Analysis for Symptom Days 46 vi Table 3.11: One-Way Sensitivity Analysis of All Model Variables 47 Table 3.12: Results of Probabilistic Sensitivity

2015 SickKids Reports

173. Propensity-weighted Long-term Risk of Urinary Adverse Events After Prostate Cancer Surgery, Radiation, or Both (PubMed)

Propensity-weighted Long-term Risk of Urinary Adverse Events After Prostate Cancer Surgery, Radiation, or Both Prostate cancer is the second most common cancer in men and has high survivorship, yet little is known about the long-term risk of urinary adverse events (UAEs) after treatment.To compare the long-term UAE incidence across treatment and control groups.Using a matched-cohort design, we identified elderly men treated with external-beam radiotherapy (EBRT; n=44 318), brachytherapy (BT; n (...) RP, RP+EBRT, and BT+EBRT experienced the highest UAE risk at 10 yr, although UAEs accrued differently over extended follow-up. The significant background UAE rate among non-cancer control individuals yields a risk attributable to prostate cancer treatment that is 17% lower than prior estimates.We show that treatment for prostate cancer, especially combinations of two treatments such as radiation and surgery, carries a significant risk of urinary adverse events such as urethral stricture

2014 EvidenceUpdates

174. Validation of the Risk Estimator Decision Aid for Atrial Fibrillation (RED-AF) for Predicting 30-Day Adverse Events in Emergency Department Patients With Atrial Fibrillation (PubMed)

Validation of the Risk Estimator Decision Aid for Atrial Fibrillation (RED-AF) for Predicting 30-Day Adverse Events in Emergency Department Patients With Atrial Fibrillation In the United States, nearly 70% of emergency department (ED) visits for atrial fibrillation result in hospitalization. The incidence of serious 30-day adverse events after an ED evaluation for atrial fibrillation remains low. This study's goal was to prospectively validate our previously reported Risk Estimator Decision (...) 497 patients between June 2010 and February 2013. Of these, 120 (24%) had greater than or equal to 1 adverse event within 30 days. A RED-AF score of 87 was identified as an optimal threshold, resulting in sensitivity and specificity of 96% (95% confidence interval [CI] 91% to 98%) and 19% (95% CI 15% to 23%), respectively. Positive and negative predictive values were 27% (95% CI 23% to 32%) and 93% (95% CI 85% to 97%), respectively. The c statistic for RED-AF was 0.65 (95% CI 0.59 to 0.71

Full Text available with Trip Pro

2014 EvidenceUpdates

175. Long-term clinical outcome of major adverse cardiac events in survivors of infective endocarditis: a nationwide population-based study (PubMed)

Long-term clinical outcome of major adverse cardiac events in survivors of infective endocarditis: a nationwide population-based study Substantial infective endocarditis (IE)-related morbidity and mortality may occur even after successful treatment. However, no previous study has explored long-term hard end points (ie, stroke, myocardial infarction, heart failure, cardiovascular death) in addition to all-cause mortality in IE survivors.A nationwide population-based cohort study was conducted (...) -cause death (aHR, 2.27; 95% CI, 2.14-2.40). Risk factors for repeat IE were older age, male sex, drug abuse, and valvular replacement after an initial episode of IE.Despite treatment, the risk of long-term major adverse cardiac events was substantially increased in IE survivors.© 2014 American Heart Association, Inc.

Full Text available with Trip Pro

2014 EvidenceUpdates

176. An exploration of the implementation of open disclosure of adverse events in the UK: a scoping review and qualitative exploration

An exploration of the implementation of open disclosure of adverse events in the UK: a scoping review and qualitative exploration An exploration of the implementation of open disclosure of adverse events in the UK: a scoping review and qualitative exploration An exploration of the implementation of open disclosure of adverse events in the UK: a scoping review and qualitative exploration Birks Y, Harrison R, Bosanquet K, Hall J, Harden M, Entwistle V, Watt I, Walsh P, Ronaldson S, Roberts D (...) , Adamson J, Wright J, Iedema R Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Birks Y, Harrison R, Bosanquet K, Hall J, Harden M, Entwistle V, Watt I, Walsh P, Ronaldson S, Roberts D, Adamson J, Wright J, Iedema R. An exploration of the implementation of open disclosure of adverse events in the UK: a scoping review and qualitative exploration

2014 Health Technology Assessment (HTA) Database.

177. Predicting major adverse cardiac events in spine fusion patients: is the revised cardiac risk index sufficient? (PubMed)

Predicting major adverse cardiac events in spine fusion patients: is the revised cardiac risk index sufficient? Observational cohort study.To determine the accuracy of the Revised Cardiac Risk Index (RCRI) in predicting major adverse cardiac events in patients undergoing spine fusion surgery of 3 levels or more.Preoperative cardiac testing is extensively guided by the RCRI, which was developed and validated in thoracic, abdominal, and orthopedic surgical patients. Because multilevel spine

2014 EvidenceUpdates

178. Meningitis B vaccine: useful in the event of an epidemic but adverse effects need to be more clearly identified

Meningitis B vaccine: useful in the event of an epidemic but adverse effects need to be more clearly identified Prescrire IN ENGLISH - Spotlight ''Meningitis B vaccine: useful in the event of an epidemic but adverse effects need to be more clearly identified'', 1 September 2014 {1} {1} {1} | | > > > Meningitis B vaccine: useful in the event of an epidemic but adverse effects need to be more clearly identified Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :   (...) |   |   |   |   |   |   |   |   |  Spotlight Meningitis B vaccine: useful in the event of an epidemic but adverse effects need to be more clearly identified The first vaccine against meningitis B has been authorised within the EU. This vaccine may be useful in the event of a meningitis epidemic, but further evaluation is required. Meningitis and other meningococcal infections are rare but serious, sometimes fatal, and can cause

2014 Prescrire

179. Time elapsed after ischemic stroke and risk of adverse cardiovascular events and mortality following elective noncardiac surgery. (PubMed)

Time elapsed after ischemic stroke and risk of adverse cardiovascular events and mortality following elective noncardiac surgery. The timing of surgery in patients with recent ischemic stroke is an important and inadequately addressed issue.To assess the safety and importance of time elapsed between stroke and surgery in the risk of perioperative cardiovascular events and mortality.Danish nationwide cohort study (2005-2011) including all patients aged 20 years or older undergoing elective (...) noncardiac surgeries (n=481,183 surgeries).Time elapsed between stroke and surgery in categories and as a continuous measure.Risk of major adverse cardiovascular events (MACE; including ischemic stroke, acute myocardial infarction, and cardiovascular mortality) and all-cause mortality up to 30 days after surgery. Odds ratios (ORs) were calculated by multivariable logistic regression models.Crude incidence rates of MACE among patients with (n = 7137) and without (n = 474,046) prior stroke were 54.4 (95

Full Text available with Trip Pro

2014 JAMA

180. An exploration of the implementation of open disclosure of adverse events in the UK: a scoping review and qualitative exploration

An exploration of the implementation of open disclosure of adverse events in the UK: a scoping review and qualitative exploration Anexplorationoftheimplementation ofopendisclosureofadverseevents intheUK:ascopingreviewand qualitativeexploration Yvonne Birks, 1* Reema Harrison, 2 Kate Bosanquet, 2 Jill Hall, 2 Melissa Harden, 3 Vikki Entwistle, 4 Ian Watt, 2 Peter Walsh, 5 Sarah Ronaldson, 2 David Roberts, 6 Joy Adamson, 2 John Wright 7 and Rick Iedema 8 1 Social Policy Research Unit, University (...) of adverse events, in terms of health care, refers to the practice of telling people if they have been harmed by a mistake when receiving care. In 2009, the National Patient Safety Agency relaunched its Being Open framework to support open disclosure in the UK. We explored how this guidance has been received, combining the literature on open disclosure with findings from interviews. We reviewed the international literature on open disclosure since 1980, identifying over 600 papers, predominantly from

2014 NIHR HTA programme